Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRIL MALEATE versus PRINIVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRIL MALEATE versus PRINIVIL.
ENALAPRIL MALEATE vs PRINIVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril is a prodrug that is hydrolyzed to enalaprilat, a potent competitive inhibitor of angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
Lisinopril is an angiotensin-converting enzyme inhibitor that decreases angiotensin II production, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Initial: 5 mg orally once daily; titrate to 10-40 mg/day in 1-2 divided doses. Target: 10-40 mg/day. Maximum: 40 mg/day. Route: Oral. Frequency: Once or twice daily.
Initial dose 10 mg orally once daily; titrate to target dose of 20-40 mg daily based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life of enalaprilat (active metabolite) is approximately 35-38 hours. This prolonged half-life supports once-daily dosing in most patients, but may require dosage adjustment in renal impairment.
Terminal elimination half-life is approximately 12 hours, with accumulation noted in renal impairment; effective half-life at steady state extends to 30-50 hours in patients with creatinine clearance <30 mL/min.
Primarily renal (60-80% as unchanged drug and metabolites, mainly enalaprilat); biliary/fecal excretion accounts for the remainder (approximately 20-30%).
Renal excretion accounts for approximately 60% of total clearance, primarily as unchanged lisinopril; fecal excretion accounts for negligible amounts.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor